ArticleCureus2024
Advanced Unresectable Differentiated Thyroid Cancer With Anaplastic Transformation: A Case Report and Review of the Literature.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Latin American Thyroid Society expert panel consensus on anaplastic thyroid cancer.Archives of endocrinology and metabolism · 2026Article
- Surgical Management and Outcomes in Advanced Thyroid Cancer: Insights from a Single-Institution Experience.Journal of clinical medicine · 2026Article
- Lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion.European thyroid journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid carcinoma (PTC) is the most common subtype of thyroid cancer (TC). Although surgery and radioactive iodine therapy (RAI) generally yield favorable outcomes, advanced cases with extensive local invasion and metastases pose significant challenges. We report the case of a 65-year-old male with advanced, inoperable PTC characterized by extensive local invasion and distant metastases. A whole-body radioiodine scan revealed no iodine-avid disease. However, following recombinant human thyrotropin (rhTSH) preparation, the patient developed severe compressive symptoms, necessitating glucocorticoid treatment. Lenvatinib monotherapy was initiated, resulting in initial symptom relief. Unfortunately, the disease rapidly progressed due to anaplastic transformation of the PTC, ultimately leading to the patient's death. This report highlights the challenges of managing advanced differentiated TC (DTC) and the risk of aggressive transformation into anaplastic TC (ATC), even with targeted therapy. It underscores the critical need for close monitoring and a multidisciplinary approach. Further research is needed to explore the role of targeted therapies, such as lenvatinib, in altering tumor biology and their long-term effects on disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.